September 6, 2026
Bonus Content: Drug Pricing Rules Now Cover 90% of the Market. Are Cheap Pharma Stocks Actually a Trap?
There’s a Quiet Plan to Shrink Your Dollar – And It Has a Name
What if we told you there’s a plan in Washington to make your dollar worth less – and it’s already in motion?
Sounds crazy. But it’s real. And it has a name.
It’s being called the “Mar-a-Lago Accord.”
The idea is to weaken the dollar on purpose – to make American exports cheaper and bring factory jobs back home.
Here’s how: tariffs on imports, pressure on other countries to lift their currencies, and a dollar pushed lower by design. That’s the strategy. The trouble is what it costs you.
Because a weaker dollar means every dollar you’ve saved buys less.
Think your savings are safe? Think again.
This won’t hit like a crash. No headline, no warning. Your dollar just buys less… then less… until a lifetime of work quietly slips away – and you never see a single withdrawal.
That’s the part nobody’s warning you about. By the time most people feel it, it’s already too late.
But you don’t have to stand for it. Smart Americans are already moving to get their wealth out of the dollar’s path – before the slide picks up speed.
See the plan – and how to fight back – before it’s too late.
Inside, you’ll get the 3 secret strategies you can put in place starting today – so a weaker dollar doesn’t decide what your money is worth tomorrow.
Drug Pricing Rules Now Cover 90% of the Market. Are Cheap Pharma Stocks Actually a Trap?
Hey there, bargain hunter. The pharma discount bin is filling up fast, and the question worth asking right now is whether those low multiples are a deal or a warning label.
Scoreboard
On August 31, the Trump administration announced MFN pricing agreements with nine additional manufacturers, bringing the total to 26 companies. The White House says that represents about 89% of the branded drug market. The new signatories are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. Sun shed over 2% the day after the deal was announced. Teva has traded around $36, up 17% year-to-date but flat since the news.
What Actually Happened
The agreements are for “most-favored-nation” prices, meaning that Medicaid will pay prices that match the administration’s MFN benchmark derived from a reference group of other wealthy countries. The administration defines an MFN price as the second lowest net price from among a group of reference countries consisting of the non-U.S. G-7 nations, Denmark, and Switzerland.
The first round of 17 deals, signed through April 2026, targeted the industry’s biggest names. The nine new companies are generally smaller, with several portfolios concentrated in specialty medicines, rare diseases, or generics. That is a different risk profile entirely.
Companies did not simply volunteer. Companies aligning with MFN pricing receive relief from threatened pharmaceutical import tariffs for a period. That is the exchange rate: agree to match the MFN benchmark on select outpatient Medicaid drugs, and the administration’s threatened pharmaceutical import tariffs stay holstered for a period.
The Supply Chain Tax Nobody Priced In
Here is the part the headline savings figure buries. Supply-chain commitments include $19.6 billion in U.S. manufacturing investment plus API contributions for a national reserve, covering drugs such as levetiracetam, clindamycin, doxycycline, metronidazole, amlodipine, and tacrolimus.
Those API contributions are not free. UCB will contribute 163 tons of levetiracetam to the Strategic Active Pharmaceutical Ingredients Reserve. Teva is contributing 45 tons of metronidazole and 4.8 tons of amlodipine, while Astellas is adding 25 kg of tacrolimus. Donated inventory is inventory you cannot sell. For a generic manufacturer already running on thin margins, that is a direct hit to cash flow.
Is It Cheap?
Teva trades at a discount to branded peers, and for good reason. Teva reported second-quarter 2026 revenue of approximately $4.1 billion, down 1% year over year, as lower generics sales, including from generic Revlimid in the U.S., weighed on results. The company targets $3.7 billion in combined 2026 revenue across its three key innovative brands and aims for operating margins near 30% by 2027.
The MFN agreement signals tighter linkage between Teva’s U.S. Medicaid pricing and international benchmarks, which could pressure U.S. margins on selected products. For Sun Pharma, the United States remains a key market for its specialty and innovative portfolio. Brokerages including Bernstein maintained an outperform rating on Sun after the announcement, but that tariff shield has an expiration date.
The deals mainly affect Medicaid and cash purchases through TrumpRx.gov, leaving private insurance prices largely unchanged unless Congress codifies and expands MFN. That limits near-term damage, but it does not eliminate it for generic-heavy portfolios where Medicaid share is considerably higher.
Bull / Base / Bear
- Bull: Tariff immunity holds for two-plus years, giving companies time to adjust product mix and grow specialty revenue. Teva’s branded neuroscience push reaches its margin targets by 2027, and the stock re-rates closer to peers.
- Base: MFN bites modestly on Medicaid lines, API contributions dent near-term cash flow, but guidance holds. Stocks drift sideways as the market waits for Congress to signal whether MFN expands beyond Medicaid.
- Bear: Congress codifies MFN across commercial payers. Generic manufacturers with no branded buffer face margin compression with no pricing lever to pull. The “cheap” multiple turns out to be the correct multiple.
Action Plan
Pfizer and Lilly signed earlier and carry diversified pipelines that absorb pricing pressure. Generic-heavy names like Teva and Sun carry more execution risk until the scope of MFN beyond Medicaid is clarified. If you hold either, watch the free cash flow guidance revision in Q3 earnings before adding.
Cheap Investor Checklist
- Is free cash flow guidance maintained after API contribution commitments are booked?
- What share of revenue comes from Medicaid versus commercial payers?
- Does Teva hit $3.7B in combined 2026 revenue across its three key innovative brands, or does generic erosion widen the gap?
- Watch for any Congressional move to extend MFN pricing to Medicare or commercial insurance.
- Track the tariff immunity window: when does it expire, and what is the renewal condition?
- Monitor SAPIR contribution quantities against gross margin line items in next quarterly filings.
Bottom Line
If MFN stays confined to Medicaid, the financial damage is manageable for most of the 26 signatories. If it migrates to commercial payers, generic manufacturers with no brand buffer become value traps, not value plays. The low multiples in pharma right now are pricing in some of this uncertainty. Whether they are pricing in enough depends entirely on where Congress goes next. Watch the legislation, not the press releases.
